
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-...
PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated …